SILVER SPRING, Maryland, July 1, 2026
The U.S. Food and Drug Administration (FDA) has granted supplemental approval for Casgevy (exagamglogene autotemcel), expanding its indication to include children aged 2 years and older with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) and transfusion-dependent beta thalassemia (TDT). The landmark decision makes Casgevy the first gene therapy approved for children as young as two years of age with sickle cell disease, providing a transformative treatment option for young patients affected by these severe inherited blood disorders. Previously authorized only for patients aged 12 years and older, the expanded indication allows physicians to intervene much earlier in disease progression, helping reduce the risk of irreversible organ damage and long-term complications. The approval further reinforces the growing impact of CRISPR/Cas9 genome-editing technology in treating rare genetic diseases while highlighting the FDA’s continued commitment to accelerating innovative therapies that address significant unmet medical needs through expedited regulatory pathways.
CRISPR Gene Editing Targets the Root Cause of Sickle Cell Disease
Casgevy is a one-time autologous gene therapy that utilizes a patient’s own hematopoietic stem cells, which are collected, genetically modified using CRISPR/Cas9 genome-editing technology, and reinfused following full myeloablative conditioning. The therapy precisely edits the patient’s stem cells to increase production of fetal hemoglobin (HbF), a naturally occurring form of hemoglobin that prevents red blood cells from developing the abnormal sickle shape responsible for painful vaso-occlusive crises. By correcting the underlying genetic mechanism rather than treating symptoms alone, Casgevy offers a disease-modifying approach capable of eliminating recurrent VOCs in patients with severe sickle cell disease.
In patients with transfusion-dependent beta thalassemia, the therapy increases both fetal hemoglobin and total hemoglobin levels, enabling many individuals to achieve long-term independence from regular red blood cell transfusions. This innovative genome-editing strategy represents one of the most significant advances in precision medicine and regenerative therapies for inherited blood disorders.
Clinical Trial Results Support Earlier Treatment for Pediatric Patients
Advertisement
The FDA’s expanded approval is supported by encouraging clinical trial data evaluating Casgevy in pediatric patients aged 5 years to less than 12 years. Among children with sickle cell disease, all eight efficacy-evaluable patients achieved the primary endpoint of experiencing no protocol-defined severe vaso-occlusive crises for at least 12 consecutive months during the first two years following treatment. In pediatric patients with transfusion-dependent beta thalassemia, eight of nine efficacy-evaluable participants achieved transfusion independence for at least twelve consecutive months, with a median duration exceeding 20 months.
Based on these clinical outcomes, combined with product characteristics and scientific evidence supporting earlier intervention, the FDA extended the indication to include children 2 years of age and older through extrapolation. While the therapy demonstrated significant clinical benefit, healthcare providers will continue monitoring patients for known treatment-related risks, including mucositis, febrile neutropenia, delayed blood cell recovery, hypersensitivity reactions, and potential off-target genome editing associated with CRISPR technology.
Historic FDA Decision Expands Access to Pediatric Gene Therapy
The approval represents another milestone in the evolution of gene-editing therapeutics, reinforcing the clinical potential of CRISPR-based medicines for inherited diseases. The FDA completed its review in only 53 days under the Commissioner’s National Priority Voucher (CNPV) Pilot Program, making Casgevy the eighth therapy approved through this accelerated initiative. The therapy has also received Orphan Drug Designation, Regenerative Medicine Advanced Therapy (RMAT) Designation, and Fast Track Designation, recognizing its importance in addressing serious unmet medical needs.
Earlier access to Casgevy enables clinicians to intervene before cumulative organ damage, impaired growth, and long-term complications develop, offering children with sickle cell disease and beta thalassemia a significantly improved opportunity for healthier lives. The latest FDA approval further establishes Vertex Pharmaceuticals as a leader in genome-editing innovation while demonstrating the transformative potential of CRISPR gene therapy to reshape the future treatment of life-threatening inherited blood disorders.
Source: FDA press release
